NASDAQ: APMDApnimed Inc Stock
$25.71+0.71 (+2.84%)
Updated Aug 4, 2026
APMD Price
$25.71
Fair Value Price
N/A
Market Cap
N/A
52 Week Low
$16.12
52 Week High
$29.15
P/E
N/A
P/B
N/A
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-0.45
Operating Cash Flow
N/A
Beta
9.15
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
APMD Overview
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. Its products include AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine APMD's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
APMD
Ranked#114 of 463
Ranked#114 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $11.07 | A | |
| $109.80 | A | |
| $8.19 | A |
Be the first to know about important APMD news, forecast changes, insider trades & much more!
APMD News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how APMD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
APMD's short-term assets ($78.16M) exceed its short-term liabilities ($40.99M)
Short-term Liabilities Financials
APMD's long-term liabilities ($96.21M) exceed its short-term assets ($78.16M)
Long-term Liabilities Financials
APMD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
There are 30 more APMD due diligence checks available for Premium users.
Valuation
APMD's financial health
Profit margin
Revenue
$84.8M
Net Income
$67.7M
Profit Margin
79.8%
Assets to liabilities
Assets
$79.0M
Liabilities
$137.2M
Debt to equity
-0.45
APMD's short-term assets ($78.16M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
APMD's long-term liabilities ($96.21M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
APMD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
APMD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$19.8M
Investing
$0.0
Financing
$24.8M
Apnimed Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.